Drug details:
Molecular formula: C₁₃H₁₀BrN₃O₂

Standard name: N-[(E)-(5-bromo-2-hydroxyphenyl)methylideneamino]pyridine-3-carboxamide

Synonyms:

Pyridine-2-carbohydrazide, N2-(2-hydroxy-5-bromobenzylideno)- N'-[(E)-(5-Bromo-2-hydroxyphenyl)methylidene]nicotinohydrazide # N'-[(E)-(5-bromo-2-hydroxyphenyl)methylidene]pyridine-3-carbohydrazide N-[(E)-(5-bromo-2-hydroxy-phenyl)methyleneamino]pyridine-3-carboxamide

Curated SMILES: O=C(N/N=C/C1=CC(Br)=CC=C1O)C1=CC=CN=C1

Evidence for compound's anti-virulence activity:

Salmonella
Related VF: TTSS (SPI-1 encode); TTSS (SPI-2 encode)
Target: Not determined
Drug effect: Efficiently affected SPI1 and SPI2 activity.
Max phase: Preclinical (in vitro)
Publication:
Negrea A, et al., 2007. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 51(8):2867-76.

Shigella
Related VF: TTSS (Type III secretion system)
Target: MxiH
Drug effect: Inhibits needle assembly.
Max phase: Preclinical (in vitro)
Publication:
Veenendaal AK, et al., 2009. Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol 191(2):563-70.